MARKET

NRXPW

NRXPW

NRX Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.78
-1.07
-13.63%
Closed 18:48 07/29 EDT
OPEN
8.29
PREV CLOSE
7.85
HIGH
8.84
LOW
6.71
VOLUME
69.10K
TURNOVER
--
52 WEEK HIGH
16.30
52 WEEK LOW
0.1301
MARKET CAP
--
P/E (TTM)
-8.0839
1D
5D
1M
3M
1Y
5Y
BRIEF-NRx Pharmaceuticals Announces Emergency Use Authorization Of ZYESAMI In Nation Of Georgia
reuters.com · 2d ago
NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil)...
PR Newswire · 2d ago
BRIEF-NRx Announces First Commercial Formulation For Zyesami
reuters.com · 07/22 10:50
NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has validated the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under appropria...
PR Newswire · 07/22 10:48
BRIEF-Nrx Pharmaceuticals Presents Evidence Zyesami™ (Aviptadil) Helps Prevent "Cytokine Storm" In Patients With Covid-19
reuters.com · 07/19 12:57
NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19
NRx Pharmaceuticals (Nasdaq: NRXP), will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10:10 EST, via the following link: https://www.terrapinn.com/template/live/landing/a0A4G00001ZmpzpUAB/10433?utm_source=&utm_medium=landin...
PR Newswire · 07/19 10:48
UPDATE 1-Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine
reuters.com · 07/12 16:26
BRIEF-NRX Pharmaceuticals Announces Partnership With Israel Institute For Biological Research To Complete Development And Commercialization Of Brilife Covid Vaccine
reuters.com · 07/12 16:16
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRXPW. Analyze the recent business situations of NRX Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About NRXPW
NRX Pharmaceuticals, Inc., formerly Big Rock Partners Acquisition Corp., is a patient-focused, clinical stage pharmaceutical company. The Company is focused on developing NRX-101. NRX-101 is an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder and ZYESAMI (aviptadil), an intravenous and inhaled drug to treat respiratory failure in COVID-19. NRX-101 is designed to offer an oral, rapid-onset and sustained home-use therapy that can extend ketamine’s anti-suicidal benefit and reduce the side effects of ketamine. The Company combines D-cycloserine (DCS), a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NRX-101 is in Phase III of clinical testing.

Webull offers kinds of NRX Pharmaceuticals Inc stock information, including NASDAQ:NRXPW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRXPW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRXPW stock methods without spending real money on the virtual paper trading platform.